Separate systems for serotonin and leptin in appetite control

Annals of Medicine

Volumn 32, Issue 3, 2000, Pages 222-232

  Halford, Jason C G ^a   Blundell, John E ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

5 Hydroxytryptamine; Appetite; Body weight; Cholecystokinin; Food intake; Leptin; Melanocortins (MC, MSH, ( )MSH, POMC); Motivation; Neuropeptide Y; OB protein; Obesity

Indexed keywords

AMPHETAMINE; CHOLECYSTOKININ; COCAINE; CORTICOTROPIN RELEASING FACTOR; ENTEROSTATIN; GALANIN; LEPTIN; LEPTIN RECEPTOR; NEUROPEPTIDE; NEUROPEPTIDE Y; OREXIN; PROOPIOMELANOCORTIN; SEROTONIN; SEROTONIN RECEPTOR; TRYPTOPHAN;

ADIPOSE TISSUE; APPETITE; CALORIC INTAKE; FOOD INTAKE; HUMAN; PRIORITY JOURNAL; REVIEW; SATIETY;

EID: 0034110321     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853890008998829     Document Type: Review

References (87)

1. Blundell JE. Pharmacological approaches to appetite suppression. Trends Pharmacol Sci 1991; 12: 147-57.
2. Halford JCG, Blundell JE. Pharmacology of appetite suppression. In: Jucker E, ed. Progress in drug research. Vol 54. Basel, Switzerland: Birkhäuser Verlag; 2000: 25-45.
3. Blundell JE. Is there a role for serotonin (5-hydroxytryptamine) in feeding? Int J Obes 1977; 1: 15-42.
4. Blundell JE, Halford JCG. Serotonin and appetite regulation: implications for the pharmacological treatment of obesity. CNS Drugs 1998; 9: 473-95.
5. Blundell JE. Serotonin and the biology of feeding. Am J Clin Nutr 1992; 55: 1555-95.
6. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38: 1083-152.
7. Halford JCG, Wanninayake SCD, Blundell JE. Behavioural satiety sequence (BSS) for the diagnosis of drug action on food intake. Pharmacol Biochem Behav 1998; 61: 159-68.
8. Tecott LH, Sum LM, Akana SF. Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature 1995; 374: 542-6.
9. Hutson PH, Donohoe TP, Curzon G. Infusion of the 5-hydroxytryptamine agonists RU-24969 and TFMPP into the paraventricular nucleus of the hypothalamus induces hypophagia. Psychopharmacology 1988; 97: 550-2.
10. Fletcher PJ, Coscina DV. Injecting 5-HT into the PVN does not prevent feeding induced by 8-OH-DPAT into the raphe. Pharmacol Biochem Behav 1993; 46: 487-91.
11. Coscina DV, Feifel D, Norbrega JN. Intra ventricular but not intra paraventricular nucleus metergoline elicits feeding in satiated rats. Am J Physiol 1994; 266: R1562-7.
12. Walsh AE, Smith KA, Oldman AD. m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology 1994; 116: 120-2.
13. Sargent PA, Sharpley AL, Williams C. 5-HT2C activation decreases appetite and body weight in obese subjects. Psychopharmacology 1997; 133: 309-12.
14. Boeles S, Williams C, Campling GM. Sumatriptan decreases food intake and increases plasma growth hormone in women. Psychopharmacology 1997; 129: 179-82.
15. Fernstorm JD. Food-induced changes in brain serotonin synthesis: is there a relationship to appetite for specific macronutrients? Appetite 1987; 8: 163.
16. Halford JCG, Smith BK, Blundell JE. Serotonin (5-HT) and serotoninergic receptors in the regulation of macronutrient intake. In: Rethouud H R, Seeley R, eds. Neural control of macronutrient selection. Baco Raton, FL, USA: CRC Press, LLC; 2000: 425-46.
17. Blundell JE, Lawton CL, Halford JCG. Serotonin, eating behaviour and fat intake. Obes Res 1995; 3: 471-6.
18. Smith BK, York DA, Bray GA. Chronic d-fenfluramine treatment reduces fat intake independent of macronutrient preference. Pharmacol Biochem Behav 1998; 60: 105-10.
19. Smith BK, York DA, Bray GA. Effects of intrahypothalamic infusion of serotonin and serotonin receptor agonists on macronutrient selection. Am J Physiol 1999; 46: 802-11.
20. Cooper SJ, Dourish CT. Multiple cholecystokinin (CCK) receptors and CCK-monoamine interactions are instrumental in the control of feeding. Physiol Behav 1990; 48: 849-57.
21. Cooper SJ. Cholecystokinin modulation of serotonergic control of feeding behavior. Ann N Y Acad Sci 1996; 780: 213-22.
22. Cooper SJ, Dourish CT, Clifton PG. CCK antagonists and CCK monoamine interactions in the control of satiety. Am J Clin Nutr 1992; 55: 291-5.
23. Cooper SJ, Dourish CT, Barber DJ. Reversal of the anorectic effect of (+)-fenfluramine in the rat by the selective cholecystokinin receptor antagonist MK-329. Br J Pharmacol 1990; 99: 65-70.
24. Stallone D, Nicolaidis S, Gibbs J. Cholecystokinin-induced anorexia depends on serotoninergic function. Am J Physiol 1989; 256: 1138-41.
25. Poeschla B, Gibbs J, Simansky KJ, Smith GP. The 5-HT1a agonist 8-OH-DPAT attenuates the satiating action of cholecystokinin. Pharmacol Biochem Behav 1992; 42: 541-3.
26. Poeschla B, Gibbs J, Simansky KJ, Greenburg D, Smith GP. Cholecystokinin-induced satiety depends on activation of 5-HT1c receptors. Am J Physiol 1993; 264: 62-4.
27. Voigt JP, Fink H, Marsden CA. Evidence for the involvement of the 5-HT1a receptor in CCK induced satiety in rats. Arch Pharmacol 1995; 351: 217-20.
28. Esfanhani N, Bedner I, Quershi GA, Sodersten P. Inhibition of serotonin synthesis attenuates inhibition of ingestive behavior by CCK-8. Pharmacol Biochem Behav 1995; 51: 9-12.
29. Voigt JP, Sohr R, Fink H. CCK-8S facilitates 5-HT release in the rat hypothalamus. Pharmacol Biochem Behav 1998; 59: 179-82.
30. Burton-Freeman B, Gietzen DW, Schneeman BO. Cholecystokinin and serotonin receptors in the regulation of fat-induced satiety in rats. Am J Physiol 1999; 276: 429-34.
31. Erlanson-Albertsson C, Mei J, Okada S, York DA, Bray GA. Pancreatic procolipase propeptide, enterostatin specifically inhibits fat intake. Physiol Behav 1991; 49: 1191-4.
32. Okada S, York DA, Bray, GA, Erlanson-Albertsson C. Enterostatin (Val-Pro-Asp-Pro-Arg), the activation peptide of procolipase selectively reduces fat intake. Physiol Behav 1991; 49: 1185-9.
33. Mei J, Erlanson-Albertsson C. Role of intraduodenally administered enterostatin in rats: inhibition of food. Obes Res 1996; 4: 161-5.
34. Lin L, York DA. Chronic ingestion of dietary fat is a prerequisite for inhibition of feeding by enterostatin. Am J Physiol 1998; 44: R619-23.
35. Dryden S, Wang Q, Frankish HM. The serotonin (5-HT) antagonist methysergide increases neuropeptide Y (NPY) synthesis and secretion in the hypothalamus of the rat. Brain Res 1995; 699: 12-8.
36. Dryden S, Frankish HM, Wang Q. Increases in feeding and neuropeptide Y (NPY) but not NPY mRNA levels in the hypothalamus of the rat following central administration of the serotonin synthesis inhibitor p-chlorophenylalanine. Brain Res 1996; 724: 232-7.
37. Dryden S, Frankish HM, Wang Q. The serotonergic agent fluoxetine reduces neuropeptide levels and neuropeptide Y secretion in the hypothalamus of the lean and obese rats. Neuroscience 1996; 72: 557-66.
38. Dryden S, Williams G. The role of hypothalamic peptides in the control of energy balance and body weight. Curr Opin Endocrinol Diab 1996; 3: 51-8.
39. Bivens CLM, Thomas WJ, Stanley BG. Similar feeding patterns are induced by perifornical neuropeptide Y injection and by food deprivation. Brain Res 1998; 782: 271-80.
40. Grignaschi G, Sironi F, Samanin R. The 5-HT1B receptor mediates the effect of d-fenfluramine on eating caused by hypothalamic injection of neuropeptide Y. Eur J Pharmacol 1995; 274: 221-4.
41. Brown CM, Coscina DV. Ineffectiveness of hypothalamic serotonin to block neuropeptide-Y-induced feeding. Pharmacol Biochem Behav 1995; 51: 641-6.
42. Currie PJ, Coscina DV. Stimulation of 5-HT2A/2C receptors within specific hypothalamic nuclei differentially antagonizes NPY-induced feeding. Neuroreport 1997; 8: 3759-62.
43. Currie PJ, Coscina DV. 5-hydroxytryptaminergic receptor agonists: effects on neuropeptide Y potentiation of feeding and respiratory quotient. Brain Res 1998; 803: 212-7.
44. Kennady JC. The role of a fat depot in the hypothalamic control of food intake in the Rat. Proc R Soc London (Biol) 1953; 140: 578.
45. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes 1998; 22: 1145-58.
46. Zhang Y, Proenca R, Maffei M, Barone M, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32.
47. Pelleymounter MA, Cillen MJ, Baker MB, Hecht R, Winters D, Boone T, et al. Effects of the obese gene product on the body weight regulation in the ob/ob mice. Science 1995; 269: 540-3.
48. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chati BT, Rabiowitx D, et al. Weight reducing effects of the plasma protein encoded by the obese gene. Science 1995; 269: 543-6.
49. Campfield LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for peripheral signal linking adiposity and central neural networks. Science 1995; 269: 546-9.
50. Chen H, Charlet O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996; 84: 491-5.
51. Lee G, Proenca R, Montez JM, Carrol KM, Darvishzadeh JG, Leed JI, et al. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996; 379: 632-5.
52. Campfield LA, Smith FJ. Overview: neurobiology of OB protein (leptin). Proc Nutr Soc 1998; 57: 429-40.
53. Coppack SW, Pinkney JH, Mohames-Ali V. Leptin production in human adipose tissue. Proc Nutr Soc 1998; 57: 461-70.
54. Mantzoros CS. The role of leptin in human obesity and disease: a review of current evidence. Ann Intern Med 1999; 130: 671-80.
55. Coleman RA, Herrmann TS. Nutritional regulation of leptin in humans. Diabetologia 1999; 42: 639-46.
56. Maffei M, Halaas J, Ravussin E, Partley RE, Lee GH, Zhang Y, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob mRNA in obese and weight-reduced subjects. Nat Med 1995; 1: 1155-61.
57. Considine RV, Sinda MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5.
58. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early onset obesity in humans. Nature 1997; 387: 903-8.
59. Erickson JC, Clegg KE, Palmiter RD. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996; 381: 415-8.
60. Erickson JC, Hollopetter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996; 274: 1704-7.
61. Smith FJ, Campfield LA, Moschera JA, Bailon PS, Burn P. Brain administration of OB protein (leptin) inhibits neuropeptide-Y-induced feeding in ob/ob mice. Regul Peptides 1998; 75: 433-9.
62. Sahu A. Evidence suggesting that galanin (GAL), melanin-concentrating hormone (MCH), neurotensin (NT), proopiomelanocortin (POMC) and neuropeptide Y (NPY) are targets of leptin signalling in the hypothalamus. Endocrinology 1998; 139: 795-8.
63. Sahu A. Leptin decreases food intake induced by melanin-concentrating hormone (MCH), galanin (GAL) and neuropeptide Y (NPY) in the rat. Endocrinology 1998; 139: 4739-42.
64. Schwartz MW, Marks J, Sipols AJ, Baskin DB, Wood SC, Kahn SE, et al. Central insulin administration reduces neuropeptide Y mRNA expression in the arcuate nucleus of food-deprived lean (Fa/Fa) but not obese (fa/fa) Zucker rats. Endocrinology 1991; 128: 2645-7.
65. Schwartz MW, Figlewicz DP, Baskin DG, Woods SC, Kahn SE, Porte JD. Insulin and the central regulation of energy balance: an update. Endocrine Rev 1994; 2: 109-13.
66. Woods SC, Seeley, RJ, Porte D, Schwartz MW. Signals that regulate food intake and energy homeostasis. Science 1998; 280: 1378-83.
67. Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG. Identification of targets of leptin action in rat hypothalamus. J Clin Invest 1996; 98: 1101-6.
68. Beck B, Kozak R, Stricker-Krongrad A, Burlet C. Neuropeptide Y release in the paraventricular nucleus of Long-Evans rats treated with leptin. Biochem Biophys Res Commun 1998; 242: 636-9.
69. Gardner JD, Rothwell NJ, Luheshi GN. Leptin affects food intake via CRF-receptor-mediafed pathways. Nature Neuroso 1998; 1: 103.
70. Kask A, Rago L, Korrovits P, Wikberg JES, Schioth HB. Evidence that orexigenic effects of melanocortin 4 receptor antagonist HSO14 are mediated by neuropeptide Y. Biochem Biophys Res Commun 1998; 248: 245-9.
71. Kask A, Rago L, Wikberg JES, Schioth HB. Evidence for involvement of the melanocortin MC4 receptor in the effects of leptin on food intake and body weight. Eur J Pharmacol 1998; 360: 15-9.
72. Leibowitz SF, Akabayashi A, Alexander JT, Wang J. Gondola steroids and hypothalamic galanin and neuropeptide Y: role in eating behaviour and body weight control in female rats. Endocrinology 1998; 139: 1771-80.
73. Lin L, York DA, Bray GA. Comparison of osborne-mendel and S5B/PL strains of rat: central effects of galanin, NPY, β-casomorphin and CRH on intake of high and low fat diets. Obes Res 1996; 4: 117-23.
74. Menzaghi F, Heinrichs SC, Pich EM. Functional impairment of hypothalamic corticotrophin releasing factor neurons with immunotargeted toxins enhances food intake induced by neuropeptide Y. Brain Res 1993; 618: 76-82.
75. Van Dijk G, Seeley RJ, Thiele TD, Friedman MI, Ji H, Wilkinson CW, et al. Metabolic, gastrointestinal, and CNS neuropeptide effects of brain leptin administration in the rat. Am J Physiol 1999; 276: r1425-33.
76. Ludwig DS, Mountjoy KG, Tatro JB, Gillette JA, Frederich RC, Flier JS, et al. Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus. Am J Physiol 1998; 37: E627-33.
77. Hagan MM, Rushing PA, Schwartz MW, Yagaloff KA, Burn P, Woods SC, et al. Role of the CNS melanocortin system in the response to over feeding. J Neurosci 1999; 19: 2362-7.
78. Mizuno TM, Kleopoulos SP, Bergen HT, Roberts JL, Priest CA, Mobbs CV. Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting in ob/ob and db/db mice, but is stimulated by leptin. Diabetes 1998; 47: 294-7.
79. Mizuno TM, Makimura H, Silverstien J, Roberts JL, Lopingco T, Mobbs CV. Fasting regulates hypothalamic neuropeptide Y, agouti-related peptide, and proopiomelanocortin in diabetic mice independent of changes in leptin or insulin. Endocrinology 1999; 140: 4551-7.
80. Fisher SL, Yagaloff KA, Burn P. Melanocortin-4 receptor: a novel signalling pathway involved in body weight regulation. Int J Obes 1999; 23: 54-8.
81. Thornton JE, Cheung CC, Clifton DK, Steiner RA. Regulation of hypothalamic proopiomelanocortin mRNA by leptin in ob/ob mice. Endocrinology 1997; 138: 5063-6.
82. Zemel MB, Xue B. Agouti/ melanocortin interactions with leptin pathways in obesity. Nutr Rev 1998; 56: 271-81.
83. Yamada J, Sugimoto Y, Ujikawa M. The serotonin precursor 5-hydroxytryphan elevates serum leptin levels in mice. Eur J Pharmacol 1999; 383: 49-51.
84. Dryden S, Brown M, King P, Williams G. Decrease plasma leptin levels in lean and obese zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine. Horm Metab Res 1999; 31: 363-6.
85. Nonogaki K, Strack AM, Dallman MF, Tecott LH. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2c receptor gene. Nat Med 1998; 4: 1152-6.
86. Lentes KU, Hinney A, Ziegler A, Rosenkranz K, Wurmser H, Barth N, et al. Evaluation of a Cys23Ser mutation within the human 5-HT2C receptor gene: no evidence for an association of the mutant allele with obesity or underweight in children, adolescents and young adults. Life Sci 1997; 61: PL9-16.
87. Jimerson DC, Wolfe BE, Metzger ED. Decreased serotonin function in bulimia nervosa. Arch Gen Psychiatry 1997; 54: 529-34.